Sign Out
In accordance with current clinical practice, if Levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. 500 mg twice daily decrements every two to four weeks). There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizures control with Levetiracetam in the add-on situation has been reached, in order to reach monotherapy on Levetiracetam.
An increase in seizure frequency of more than 25% has been reported in 14 and 26% of the Levetiracetam and placebo treated patients, respectively. The administration of Levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.
Effects on ability to drive and use machines: No studies on the effects on the ability to drive and use machines have been reported. Due to possible different individual sensitivity, some patients might experience, somnolence or other central nervous system related symptoms, at the beginning of the treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery.
Use in Pregnancy & Lactation: There are no adequate data from the use of Levetiracetam in pregnant woman. The potential risk for human is unknown. Levetiracetam should not be used during pregnancy unless clearly necessary. Discontinuation of antiepileptic treatments may result in disease worsening, harmful to the mother and the fetus. No data are available on the presence of Levetiracetam in human breast milk. Therefore, breast-feeding is not recommended.
